ArticleRenal failure2026
Biological age acceleration and cardiovascular-kidney-metabolic syndrome progression: evidence from UK Biobank and NHANES.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe examined associations of biological age acceleration with cardiovascular-kidney-metabolic (CKM) syndrome progression and baseline stage burden.
methodsLongitudinal analyses included 326,218 UK Biobank participants, and cross-sectional analyses included 5,228 NHANES adults. PhenoAge and KDMAge acceleration were residuals from regressing each biological age measure on chronological age. We modeled two UK Biobank transitions using cause-specific Cox and competing-risk models and compared NHANES stages using survey-weighted logistic regression.
resultsOver a median 13.48 years, 2,567 participants progressed from stage 0/1 to stage 2/3 and 42,835 from stage 1 or 2/3 to stage 4. Per 1-SD increment, PhenoAge acceleration was associated with both transitions [hazard ratios (HRs) 1.234, 95% confidence interval (CI) 1.189-1.281; HR 1.208, 95% CI 1.197-1.218]. KDMAge acceleration showed corresponding HRs of 1.229 (95% CI 1.180-1.280) and 1.220 (95% CI 1.207-1.232), all
conclusionsBiological age acceleration was associated with CKM progression and baseline burden. KDMAge comparability remains uncertain. Incremental predictive and clinical utility remained untested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.